Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 2/20 | 0.58 |
| ▸ | FUT6 | P51993 | 4/20 | 0.58 |
| ▸ | KRAS | P01116 | 2/20 | 0.57 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.56 |
| ▸ | HINT1 | P49773 | 1/20 | 0.55 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26622675 | 0.94 | NT5E (0.61) | TGM2NT5EFUT6KRASFUT5 | |
| SCHEMBL26622655 | 0.89 | TGM2 (0.66) | TGM2NT5EKRASFUT5P2RY2 | |
| SCHEMBL26208040 | 0.87 | NT5E (0.58) | TGM2NT5EFUT6KRASP2RY2 | |
| SCHEMBL26622717 | 0.87 | TGM2 (0.65) | TGM2NT5EKRASFUT5P2RY2 | |
| SCHEMBL26207486 | 0.87 | TGM2 (0.65) | TGM2NT5EKRASFUT5P2RY2 | |
| SCHEMBL26622665 | 0.87 | TGM2 (0.68) | TGM2NT5EKRASFUT5P2RY2 | |
| SCHEMBL26622787 | 0.87 | TGM2 (0.70) | TGM2NT5EKRASFUT5P2RY2 | |
| SCHEMBL26622676 | 0.87 | HINT1 (0.62) | TGM2NT5EHINT1 | |
| SCHEMBL26209516 | 0.87 | TGM2 (0.66) | TGM2NT5EKRASFUT5P2RY2 | |
| SCHEMBL26624153 | 0.87 | TGM2 (0.66) | TGM2NT5EKRASFUT5P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | RNGTT, RNMT, NSUN2 | TGM2 2548/4885NT5E 803/4885FUT6 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.